Hajdu-Cheney syndrome (HCS) is a rare connective tissue disease, with fewer than 100 cases reported worldwide.1 Hallmark features include acro-osteolysis (i.e., resorption of the distal phalanges of the hands and feet), osteoporosis, facial dysmorphisms, and craniofacial and dental abnormalities. Patients often have short stature and can have neuroanatomical deformities causing intellectual disabilities. These patients can…
Think about it. Most rheumatology labs are stuck in the 1960s. Translational biomarker research looks excellent on paper and in theory. However, many barriers exist from the bench to the bedside. This article highlights this problem for the rheumatology community and proposes practical solutions. Case in Point For an example, let’s examine systemic lupus erythematosus…
If you’ve been a long-time reader of The Rheumatologist, you may have noticed that things look just a little different in this issue. The logo has changed, the font appears distinct, and the bylines are, for lack of a better term, aligned differently. If you’re looking at this online, the menus have changed somewhat, and…
The ACR journal, Arthritis & Rheumatology has introduced a new educational series, with the complement system first in focus. “This isn’t simplified immunology for trainees,” says Dr. Bucala. “It’s for everyone.”
The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…
Rheumatologists consider ways to encourage racial and ethnic diversity among students and in the workforce in the aftermath of the Supreme Court’s ruling that ends affirmative action in higher education.
The AMA’s Physician Practice Information Survey is seeking updated data on practice costs to inform Medicare physician payment. If your practice receives a request to participate, complete this important survey to help ensure accurate payment.
Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
From Oct. 15–Nov. 15, all donations to RheumPAC will be amplified by matching contributions, so it’s the best time to make your yearly investment. Donors above the silver level will be invited to a special event at ACR Convergence 2023.
The long-awaited list of the first 10 Part D drugs to be included in the new Medicare Price Negotiation process includes the commonly prescribed rheumatology drugs Enbrel and Stelara. Initial negotiations with the drug manufacturers will begin this fall.